Organogenesis Holdings Inc.

ORGO • Drug Manufacturers - Specialty & Generic

$1.71

▲ +0.07 (+4.27%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$220.03M

Crecimiento

—

Flujo de caja

3/5

Tendencia

Mostly stable

Evidencia

Crecimiento positivo de ingresos · 5.1%Múltiplo de ganancias razonable · 17.73Nivel de deuda manejable · 0.31Liquidez saludable · 3.62

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 1:32 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1.71

Change4.27%

Shares Out128.67M

Market Cap$220.03M

Enterprise Value$240.89M

52W Range1.73 - 7.08

Beta1.33

P/E-2.44

P/S0.48

P/B1.48

P/FCF5.67

EV/Sales0.53

Price$1.71

Change4.27%

Shares Out128.67M

Market Cap$220.03M

Enterprise Value$240.89M

52W Range1.73 - 7.08

Beta1.33

P/E-2.44

P/S0.48

P/B1.48

P/FCF5.67

EV/Sales0.53

EV/EBITDA-86.74

EV/FCF6.21

Earnings Yield-41.01%

FCF Yield17.64%

Dividend Yield0.00%

Gross Margin75.57%

Oper. Margin9.92%

Profit Margin6.58%

Debt/Eq0.31

Current Ratio3.62

Quick Ratio3.32

Target$2.50

Target Upside46.20%

Target Median$2.50

Target Range2.00 - 3.00

Volume524.17K

Avg Volume1.06M

EPS Surprise-0.08

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

52/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

45/100

Atractivo del precio

Barata o cara hoy

86/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 5.1%Múltiplo de ganancias razonable · 17.73Nivel de deuda manejable · 0.31Liquidez saludable · 3.62

Analyst view

Analyst sentiment and price target

ORGO

Analyst sentiment

Based on 6 analyst votes · 2026-09-05

83/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$3.00

Promedio

$3.00

Mediana

$3.00

Alto

$3.00

Resumen de la compañía

IPO: 1/5/2017

Industria: Drug Manufacturers - Specialty & Generic

P/B i: 1.48

Deuda / Patrimonio i: 0.31

Margen operativo: 9.92%

Margen neto: 6.58%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.31

Ratio corriente: 3.62

Ratio rápido: 3.32

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Grow Brian

Transacción: 01/10/2025

VENTA

Cambio

-958

Precio

$1.24

Presentación

04/24/2026

Tipo

VENTA

Grow Brian

Transacción: 01/10/2025

COMPRA

Cambio

+958

Precio

$1.24

Presentación

04/24/2026

Tipo

COMPRA

Driscoll Michael Joseph

Transacción: 03/09/2026

COMPRA

Cambio

+10,000

Precio

$2.67

Presentación

03/11/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Grow Brian	VENTA	-958	$1.24	01/10/2025	04/24/2026
Grow Brian	COMPRA	+958	$1.24	01/10/2025	04/24/2026
Driscoll Michael Joseph	COMPRA	+10,000	$2.67	03/09/2026	03/11/2026
Leibowitz Arthur S	COMPRA	+5,000	$2.68	03/09/2026	03/11/2026
Cavorsi Robert	VENTA	-700	$3.21	03/01/2026	03/03/2026
Freedman Lori	VENTA	-14,411	$3.84	02/18/2026	03/03/2026
Cavorsi Robert	VENTA	-5,487	$3.84	02/18/2026	03/03/2026
Francisco David	VENTA	-14,687	$3.84	02/18/2026	03/03/2026
Bilbo Patrick	VENTA	-16,375	$3.84	02/18/2026	03/03/2026
Grow Brian	VENTA	-11,887	$3.84	02/18/2026	03/03/2026
Gillheeney Gary S.	VENTA	-91,311	$3.84	02/18/2026	03/03/2026
Montecalvo Antonio S.	VENTA	-3,778	$3.84	02/18/2026	03/03/2026
McGuire Patrick	OTRO	0	Not reported	02/18/2026	02/27/2026
Korfin Michele Ilene	COMPRA	+48,828	Not reported	02/18/2026	02/20/2026
Lustig Garrett	COMPRA	+48,828	Not reported	02/18/2026	02/20/2026
Duraibabu Prathyusha	COMPRA	+48,828	Not reported	02/18/2026	02/20/2026
Quintero Gilberto	COMPRA	+48,828	Not reported	02/18/2026	02/20/2026
Montecalvo Antonio S.	COMPRA	+23,162	$3.84	02/18/2026	02/20/2026
Montecalvo Antonio S.	COMPRA	+40,625	Not reported	02/18/2026	02/20/2026
Leibowitz Arthur S	COMPRA	+48,828	Not reported	02/18/2026	02/20/2026

Sobre la compañía

Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

Fuente - Link

Competidores

ANGO BCYC CMPX EBS EOLS ESPR MNPR SIGA SNDL VREX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

BlackRock Inc. Purchases Shares of 7,249,528 Organogenesis $ORGO

BlackRock Inc. acquired a new position in Organogenesis (NASDAQ: ORGO) in the quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 7,249,528 shares of the company's stock, valued at approximately $17,616,000. BlackRock Inc. owned 5.63% of Organogenesis as of its most recent

Defense World

Organogenesis Q2 Earnings Call Highlights

Organogenesis NASDAQ: ORGO reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for Medicare & Medicaid Services, while management pointed to sequential improvement in product sales and market share gains.

MarketBeat

Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript

Seeking Alpha

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2026.

GlobeNewsWire

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced published results from a prospective, multicenter, randomized controlled trial (RCT) evaluating Affinity plus standard of care (SoC) compared to SoC alone in the management of complex venous leg ulcers (VLUs). The results were published in the Journal of Wound Care demonstrating statistically significant improvements in wound closure at weeks 12 and 16 for the Affinity + SoC group across two wound duration strata studied, providing compelling new peer-reviewed evidence for one of the most difficult-to-treat wound populations in chronic wound care.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	-0.29	-0.37	-0.08
2026-02-26	0.215	0.31	0.095
2025-11-06	0.21	0.18	-0.03
2025-08-07	0.07	-0.09	-0.16
2025-05-08	0.04	-0.13	-0.17
2025-02-27	-0.03	0.04	0.07
2024-11-12	0.01125	0.09	0.07875
2024-08-08	-0.02	-0.13	-0.11
2024-05-09	-0.016	-0.02	-0.004
2024-02-29	-0.00215	-0.00431	-0.00216
2023-11-09	0.005	0.02	0.015
2023-08-09	0.025	0.04	0.015